Scholarlink

Background <p>Liver hepatocellular carcinoma (LIHC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic options for advanced stages. Cytoskeleton-associated protein 5 (CKAP5), a key regulator of microtubule dynamics, has emerged as a potential oncogene in multiple cancers, yet its precise role and clinical relevance in LIHC pathogenesis and tumor immunity are not fully understood.</p> Methods <p>We systematically evaluated CKAP5 expression patterns using multi-omics data from TCGA, GEO, and the Human Protein Atlas. Prognostic significance was assessed through Kaplan–Meier survival analysis, Cox regression, and ROC curves. The association between CKAP5 and the tumor immune microenvironment was investigated via immune cell infiltration analysis, immune checkpoint correlation, and single-cell RNA sequencing. Mechanistic insights were explored through gene set enrichment analysis (GSEA), transcription factor activity inference, and protein–protein interaction network construction. Functional validation was performed using CRISPR-Cas9-mediated CKAP5 knockdown in HepG2 cells, followed by comprehensive assays measuring proliferation, migration, and invasion capabilities.</p> Results <p>CKAP5 was significantly overexpressed in LIHC tissues at both mRNA and protein levels, and its elevated expression correlated strongly with advanced tumor stage, poor differentiation, and unfavorable patient survival. CKAP5 expression was associated with distinct immune cell infiltration patterns and positively correlated with key immune checkpoint molecules (PD1, PDL1, and CTLA4). Bioinformatic analyses further revealed a potential mechanistic link between CKAP5 and immunosuppressive signaling pathways, including JAK-STAT and NF-κB. Functional studies demonstrated that CKAP5 depletion markedly suppressed LIHC cell proliferation, colony formation, migration, and invasion.</p> Conclusions <p>Our integrated analysis establishes CKAP5 as a critical promoter of LIHC progression and a modulator of the tumor immune microenvironment. These findings nominate CKAP5 as a promising prognostic biomarker and a potential therapeutic target, providing new insights into LIHC pathogenesis and future treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CKAP5: Unraveling Its Crucial Function in Liver Hepatocellular Carcinoma Progression and Prognosis

  • 期刊论文

  • 发表日期：

    2025年12月23日

查看全文
  • Lusheng Liao,
  • Yawen Li,
  • Bixiao Wei,
  • Mei Fei,
  • Fengdie Huang,
  • Yuejiao Huang,
  • Yuhong Hu,
  • Shanshan Xiao,
  • Mingyou Dong,
  • Qinqin Long

摘要

Background

Liver hepatocellular carcinoma (LIHC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic options for advanced stages. Cytoskeleton-associated protein 5 (CKAP5), a key regulator of microtubule dynamics, has emerged as a potential oncogene in multiple cancers, yet its precise role and clinical relevance in LIHC pathogenesis and tumor immunity are not fully understood.

Methods

We systematically evaluated CKAP5 expression patterns using multi-omics data from TCGA, GEO, and the Human Protein Atlas. Prognostic significance was assessed through Kaplan–Meier survival analysis, Cox regression, and ROC curves. The association between CKAP5 and the tumor immune microenvironment was investigated via immune cell infiltration analysis, immune checkpoint correlation, and single-cell RNA sequencing. Mechanistic insights were explored through gene set enrichment analysis (GSEA), transcription factor activity inference, and protein–protein interaction network construction. Functional validation was performed using CRISPR-Cas9-mediated CKAP5 knockdown in HepG2 cells, followed by comprehensive assays measuring proliferation, migration, and invasion capabilities.

Results

CKAP5 was significantly overexpressed in LIHC tissues at both mRNA and protein levels, and its elevated expression correlated strongly with advanced tumor stage, poor differentiation, and unfavorable patient survival. CKAP5 expression was associated with distinct immune cell infiltration patterns and positively correlated with key immune checkpoint molecules (PD1, PDL1, and CTLA4). Bioinformatic analyses further revealed a potential mechanistic link between CKAP5 and immunosuppressive signaling pathways, including JAK-STAT and NF-κB. Functional studies demonstrated that CKAP5 depletion markedly suppressed LIHC cell proliferation, colony formation, migration, and invasion.

Conclusions

Our integrated analysis establishes CKAP5 as a critical promoter of LIHC progression and a modulator of the tumor immune microenvironment. These findings nominate CKAP5 as a promising prognostic biomarker and a potential therapeutic target, providing new insights into LIHC pathogenesis and future treatment strategies.